ecancermedicalscience · 2016 · 20 citations · 29 references
Capecitabine is an acceptable and more convenient alternative to infusional 5-FU in the CRT for localised SCCAC, offering similar clinical CRR to those reported by phase-III trials.
29
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher, A. Liberati, Jennifer Tetzlaff et al. · BMJ · 2009 · 82.3K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.1K citations · Full text
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
David Cunningham, Naureen Starling, Sheela Rao et al. · New England Journal of Medicine · 2008 · 2.3K citations